KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Acquisitions (2016 - 2022)

Eli Lilly (LLY) has disclosed Acquisitions for 11 consecutive years, with $327.2 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Acquisitions changed N/A year-over-year to $327.2 million, compared with a TTM value of $327.2 million through Dec 2022, down 56.22%, and an annual FY2022 reading of $327.2 million, down 56.22% over the prior year.
  • Acquisitions was $327.2 million for Q4 2022 at Eli Lilly, down from $747.4 million in the prior quarter.
  • Across five years, Acquisitions topped out at $6.9 billion in Q1 2019 and bottomed at $327.2 million in Q4 2022.
  • Average Acquisitions over 4 years is $2.2 billion, with a median of $798.3 million recorded in 2020.
  • The sharpest move saw Acquisitions crashed 87.72% in 2020, then dropped 12.0% in 2021.
  • Year by year, Acquisitions stood at $6.9 billion in 2019, then plummeted by 87.72% to $849.3 million in 2020, then dropped by 12.0% to $747.4 million in 2021, then crashed by 56.22% to $327.2 million in 2022.
  • Business Quant data shows Acquisitions for LLY at $327.2 million in Q4 2022, $747.4 million in Q1 2021, and $849.3 million in Q1 2020.